Evidence map›Paper›PMID 40059422›Full record

ReviewCurrent neuropharmacology2025

The Dual Role of Microglia in Multiple Sclerosis and its Implications for Diagnostics and Repair.

Melissa T Goulart, Davi T U Queiroz, Fabíola M Ribeiro

Abstract readReview
In one paragraph

Review in Current neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Melissa T GoulartDepartment of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Davi T U QueirozDepartment of Neurology, Felício Rocho Hospital, Belo Horizonte, Brazil.
Fabíola M RibeiroDepartment of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Funding

CNPq, Conselho Nacional de Desenvolvimento Científico e Tecnológico 441719/2020-1FAPEMIG, Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-03921-22, APQ-00140-23, RED-00067-23
6 · The paper itself

Abstract

Microglia play a crucial role in the development, immune surveillance, and repair of the central nervous system. These cells play a multifaceted role in multiple sclerosis (MS), with evidence suggesting that microglia can promote both active inflammation and remyelination. For instance, it has been shown that microglia can support the development of oligodendrocytes and phagocytose myelin debris, thus aiding in proper remyelination. However, microglia overactivation in MS lesions exacerbates neuroinflammation by releasing inflammatory cytokines and facilitating the activation of astrocytes and immune cells, promoting demyelination and, ultimately, driving MS pathology. In fact, it has been shown that there is a correlation between activated microglia patterns and the chronicity of MS. Thus, although it is difficult to be certain whether these cells are friends or foes, there is no doubt that microglia will be a relevant target for MS diagnosis and treatment in the future, when further research will help to clarify the role of these cells in MS. MRI and PET scan allow evaluation of microglia/macrophages biomarkers, facilitating the clinical assessment of a patient's disease stage. Moreover, new microglia-specific markers are being discovered, which will increase diagnostic precision, helping to identify active and chronic MS lesions. Because microglia are involved in all MS phases, these cells are also an important drug target. In this review, we focus on the current understanding of the role of microglia in MS progression as well as on the evidence supporting both inflammatory and reparative functions of these cells. We will also review how microglia may yield new biomarkers for MS diagnosis and serve as a potential target for therapy.

Indexed as

MicrogliaMultiple SclerosisAnimalsHumansdemyelinationdisease-modifying drugs.microgliaMultiple sclerosisneuroinflammationoligodendrocytes

Identifiers

PMID40059422
PMCPMC12606663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.